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Abstract
Background: CD8+ T cell responses are often detected at large magnitudes in HIV-infected subjects, and eliciting these
responses is the central aim of many HIV-1 vaccine strategies. Population differences in CD8+ T cell epitope specificity will
need to be understood if vaccines are to be effective in multiple geographic regions.
Methodology/Principal Findings: In a large Kenyan cohort, we compared responsive CD8+ T cell HIV-1 Env overlapping
peptides (OLPs) to Best Defined Epitopes (BDEs), many of which have been defined in clade B infection. While the majority
of BDEs (69%) were recognized in this population, nearly half of responsive OLPs (47%) did not contain described epitopes.
Recognition frequencies of BDEs were inversely correlated to epitopic sequence differences between clade A1 and BDE
(P=0.019), and positively selected residues were more frequent in ‘‘new’’ OLPs (without BDEs). We assessed the impact of
HLA and TAP binding on epitope recognition frequencies, focusing on predicted and actual epitopes in the HLA B7
supertype.
Conclusions/Significance: Although many previously described CD8 epitopes were recognized, several novel CD8 epitopes
were defined in this population, implying that epitope mapping efforts have not been completely exhausted. Expansion of
these studies will be critical to understand population differences in CD8 epitope recognition.
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Introduction
The immunodominance of T cell responses, or the relative
proportion of the overall response attributable to any one given
epitope, is governed by many factors[1]. While most intracellular
pathogens are processed in the cytosol into thousands of peptides,
only a few of these will generate epitope-specific CD8+ T cell
responses. Successful epitopes must ‘‘pass’’ several steps before
generating a response, including proteosomal cleavage, stability in
the cytosol, ability to bind Transporter associated protein (TAP)
and Human leukocyte antigen (HLA) alleles, and finally
recognition by an appropriate T cell receptor (TCR). For
pathogens such as human immunodeficiency virus (HIV), in
addition to the above factors, the repertoire of available epitopes
may critically differ between different viral strains.
In HIV infection, CD8+ T cell responses can be very broad and
large in magnitude; in clade B-infected cohorts, .60 distinct
epitope-specific responses have been measured in a single
chronically infected subject[2], and the total HIV-specific CD8+
T cell response can be .15% of circulating CD8+ T cells in
blood[3]. It has further become evident that not all of these
responses are important for control of viral replication and
prevention of disease[3,4]. A better understanding of factors that
influence CD8+ T cell recognition in HIV infection, particularly
in the setting of different HIV clades, is of critical importance for
HIV-1 vaccine efforts.
The cross-reactivity of HIV-specific CD8+ T cell responses has
been addressed in several populations, which have found modest
degrees of cross-clade reactivity, with some clade-specific responses
[5,6,7,8,9]. Incomplete cross-reactivity poses a problem for the
accurate assessment of HIV-specific CD8+ T cell responses, as a
portion of responses will be missed due to differences between the
sequence used for screening and the one that primed an
individual’s responses in vivo. Consensus sequences are biased, as
by definition these are mismatched to an individual’s autologous
quasispecies. OLP libraries based on autologous sequences
demonstrated that .30% more responses can be detected when
compared to a consensus OLP library[10]. However, this
approach is costly and impractical for screening large populations.
The optimal methods for defining HIV-specific CD8+ T cell
responses continue to be debated. In addition to assessing multiple
functional parameters[11], an important consideration is selection
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accounts for the genetic diversity of HIV-1, and matches the
HIV-1 strains that are circulating in the study population. Because
HIV-1 often varies or ‘‘toggles’’ between two amino acids at a
given position, inclusion of these toggle peptides in combination
was demonstrated to increase detection frequency[12]. Another
strategy to increase detection sensitivity and account for HIV-1
diversity has been the use various clade or group M ancestral
sequences, which phylogenetically share similarity with a greater
number of circulating strains than any given circulating sequence
itself, and this has been met with mixed success for increasing
sensitivity[13,14]. One report suggested that clade C peptides were
better than clade B peptides at detecting reponses in a clade B-
infected population[15].
Most of these strategies detect overlapping sets of HIV-specific
T cell responses, yet the extent to which epitope recognition
between populations differs, particularly where circulating strains
and HLA allele frequencies differ, remains in question[16]. Other
approaches to characterize the breadth and specificity of CD8+ T
cell responses include the use of epitope prediction algorithms and
previously defined epitopes, of which many have been defined in
HIV-infected subjects. However, the majority of HIV research
until recently has focused on clade B, which accounts for only a
small percentage of HIV-1 infections globally[17]. Therefore,
previously described HIV epitopes are biased towards well-studied
populations that do not represent the majority of HIV-infected
subjects, and studies that compare epitope recognition between
populations are important to guide the design of vaccines that aim
to be efficacious in multiple populations.
We assessed factors influencing HIV-1 Env CD8+ T cell epitope
recognition in a large Kenyan population, where clade A1
comprises the majority of circulating sequences. A variety of
factors known to influence epitope recognition, including HLA
restriction, frequency, and peptide binding capabilities, HIV
genetic diversity, and processing-related factors (TAP binding,
proteosomal cleavage), were investigated. We also determined
whether recognition of particular Env epitopes was associated with
altered disease progression. These data demonstrate that while
substantial overlap existed between the epitopes recognized in our
study and those previously described, there were numerous
instances of clade-specific epitopes. A better understanding of
how CD8+ T cell responses differ in populations infected by
different HIV clades has important implications for the design of
cross-clade HIV vaccinogens.
Materials and Methods
Study subjects
Study subjects were enrolled in this study from a well-
characterized female sex worker cohort based in Nairobi, Kenya.
All gave informed consent to participate in this study, which was
approved by the Institutional Review Boards at Universities of
Manitoba and Nairobi. Subjects in this longitudinal cohort
are sampled every 6 months, and CD4 counts measured for
calculating disease progression. To assess various stages of disease
progression, we calculated the number of years from enrollment
until consecutive CD4 levels dropped below 200, 350, and
500 cells/ul of blood, and below 15% of T cells. At least two CD4
counts below each cut-off were used to decrease the influence of
transient decreases. Subjects who did not progress during #5 years
of follow-up, and those who progressed after a gap in follow-up of
$3 years were excluded from this analysis. All subjects were
HLA typed using a taxonomy-based sequencing method,
as described elsewhere [18].
Peptides and IFN-c Elispot assays
The overlapping peptide (OLP) library used in this study was
comprised of 158 15mers overlapping by 10 amino acids,
assembled into 26 pools, was used to screen peripheral blood
mononuclear cells (PBMC) of HIV-infected subjects for Elispot
responses (n=61). The sequence used for the OLP library
was a clade A1 isolate from Uganda (Accession
no. U15119). Elispot assays were conducted as previously
described[19]. 96-well nitrocellulose plates were coated with
primary IFN-c monoclonal antibody (Mabtech), and blocked with
RPMI 10% fetal bovine serum (R-10). Freshly isolated PBMCs
were incubated overnight at 2610
5 per well in duplicate with
peptide pools, with each peptide at 3 ug/ml, or with individual
peptides at 10 ug/ml. Plates were developed the following day
using Mabtech and Biorad reagents, and dried plates were
counted on an automated Elispot reader. Positive responses were
defined as those more than double negative control and $50 spot-
forming units (SFU) per million PBMCs. To be conservative in
estimating response breadth, responses to 2 overlapping peptides
were called one response; to 3 overlapping peptides were called 2
responses.
Analysis of positive selection
Positive selection in HIV-1 Env was determined using sequences
in the Los Alamos HIV Sequence database and the QUASI
program[20]. QUASI is a codon-based method that measures
empirical dN/dS ratios at each codon and compares these
statistically to neutral dN/dS ratio using two-binomial distribu-
tion. The null hypothesis is that all mutations on a given codon
should be equal (dN/dS=1). If non-synonymous substitutions are
more abundant than expected, the null hypothesis is rejected, and
positive selection is determined to be occurring at that site.
QUASI is independent of phylogeny and appropriate for large-
scale (.100) sequence analysis.
ITOPIA
TM HLA binding assays
These assays were carried out using the iTopia Epitope Discovery
System Kit (Beckman Coulter). These assays utilize microtitre plates
pre-coated with the B*0702 MHC monomer folded correctly via b2
microglobulin (b2M) and a placeholder peptide. Peptides of interest
(9mers), including positive controls, were resuspended in DMSO at
[10 mM], and diluted 1:90 in renaturation buffer prior to use.
Stripping buffer was used to remove placeholder peptide and b2M,
followed by washing three times with wash solution and immediate
addition of renaturation mixture (renaturation buffer, anti-HLA-
ABC-FITC conjugated monoclonal antibody, b2Ma n dd d H 2O).
Diluted peptide was added and incubated for 18 hrs at 20uCw i t h
continuous, gentle shaking. Plates were then washed 3 times with wash
solution, wells resuspended in dilution buffer, and read in a
fluorimeter. Data was analyzed using iTopia software, and presented
as percentage of positive control peptide binding.
Statistical analyses
We used Fisher’s Exact Test to determine HLA-OLP associa-
tions (and Boneferoni test for multiple comparisons), Spearman’s
Rank correlation to determine associations between response
frequency and HIV diversity, and Mann Whitney tests to
determine differences between groups of continuous variables.
Results
We measured IFN-c Elispot responses to Env OLPs in a large
HIV-infected cohort (n=82). For the majority of subjects, Env
pool-specific responses were confirmed at the individual peptide
Mapping Clade A1 CD8 Epitopes
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detected, and 34% of Env OLPs (53/158) were recognized at least
once. After correcting for overlapping responses (see Methods),
165 epitope-specific responses were measured (mean 2.7 Env
peptides per subject, n=61). Clustering of epitopes was evident,
with the majority of epitopes found in the more conserved regions
of HIV-1 Env (Fig. 1a), as has been described previously[21].
Despite being a smaller protein, gp41-specific responses were
greater in frequency as compared to gp120-specific responses (133
responses to 58 peptides vs. 82 responses to 100 peptides, 2.29 vs.
0.82 responses/OLP, p,0.0001, Chi-square test). One possible
explanation for these data is that gp41 is more
conserved than gp120, and therefore is a closer match
to the OLP sequence used for screening. The mean and
median magnitudes of responses were 583 and 363 SFU/million
PBMCs, respectively (range 53–3578 SFU/million).
Given that there are several well-defined epitopes for HIV-1
Env, we compared the OLPs that elicited responses in our study
with the list of Best Defined Epitopes (BDEs) for Env published in the
Los Alamos HIV Immunology database[22]. Many BDEs were
frequently targeted in our study, often at high magnitudes,
confirming that the Best Defined Epitope list is relevant in this
divergent population. The majority of BDEs (69%, 18/26) were
targeted by $1 subject in our study, 54% (14/26) by $2 subjects,
and 32% (9/26) by $3 subjects. However, there were several
instances of BDEs that were not recognized by the subjects in our
OLP screen (Table S1), and several responses to OLPs that have
not previously been shown to contain BDEs (Table 1).
Influence of HIV genetic diversity on epitope recognition
frequencies
Many factors could explain discordances between OLPs
recognized in our study and the BDE list. For example, sequence
differences between the clade A1 (used in our OLP library) and the
BDE (in most cases clade B) could result in clade-specific epitope
targeting. We calculated the number of differences between BDEs
and the corresponding epitope sequence of the OLP library, and
found an inverse correlation between the number of amino acid
differences and the frequency at which that OLP was recognized
(Fig. 1b, r
2=20.457, P=0.019). A similar inverse correlation was
observed between number of amino acid differences (consensus or
ancestral A1 vs. BDE) and OLP recognition frequency
(r
2=20.399, P=0.043), demonstrating that sequence differences
between clades A1 and B correlate with less frequent recognition
of BDEs in a clade A1-infected population. For example, only one
of the commonly recognized epitopes (OLP-8, recognized by
.10% of subjects) had substantial amino acid differences ($2)
between clade A1 and B (Table S1). Conversely, for peptides such
as OLP-62, where six amino acid differences exist between the
OLP sequence and BDE, it is not surprising that this BDE was not
recognized in clade A1-infected subjects (Table 1). These data
suggest that conserved BDEs are recognized at a higher frequency
than BDEs that vary in sequence from clade A1.
Since the majority of epitopes cluster in conserved regions of
HIV-1 Env (Fig. 1a), we next compared the frequencies of
positively selected residues within epitopic and non-epitopic
regions. Positive selection, as determined by comparing the rate
of non-synononous over synonomous mutations, is indicative of
population level selection pressure at any particular residue, and
also regions of the HIV genome that more readily accommodate
sequence variation. Prior analyses of HIV sequences from the Los
Alamos HIV Seqeunce database demonstrated evidence of
positive selection at 288 of 856 Env amino acid residues[20].
Including only OLPs recognized by .5% of our study population
($4 subjects, n=17), no differences in positive selection were
apparent between residues located inside versus outside of
responsive OLPs (34 vs. 33%). We next compared selection within
OLPs that contained or lacked BDEs, and found that responsive
OLPs without BDEs had a higher rate of positively selected
residues compared to those containing BDEs (44% vs. 29%,
P=0.04, Fig. 1c). Given our data that sequence differences can
have a negative impact on recognition frequency, these analyses
suggest that new epitopes might not have been recognized
previously because they lie in regions of HIV that are less
evolutionarily constrained and therefore easily escapable, remov-
ing potential epitopes from circulation in a given population.
Although sequence conservation within an OLP increased its
recognition frequency, there were examples where sequence
difference alone appeared to have less impact on CD8 recognition.
The most obvious examples were OLPs that were identical
between clades A1 and B, yet have no epitopes described to date
(i.e. OLP-13, 113, 114; Table 1). There were also examples of
OLPs containing a BDE that were targeted in spite of sequence
differences (i.e. OLP-139). This could be because sequence
differences occurred in the TCR recognition portion of the
epitope, leaving epitope-HLA binding intact (Table S1). Retention
of HLA binding has been shown previously to be an important
predictor of cross-clade reactivity, presumably because an
appropriate TCR can be induced as long as the epitope is still
presented[7]. The reasons why intact epitopes were recognized by
this population and not those studied previously, despite HLA
similarities, were less clear. It is important to note that many OLPs
containing intact BDEs (ie, OLP-7, 110, and 169, Table S1) were
frequently recognized, cross-clade epitopes in this cohort, which
could be useful in HIV vaccines.
Clade A1-specific epitopes recognized in our OLP screen
We observed some examples of frequently recognized epitopes
that appear to be clade A1-specific. OLPs-147, 148, and 149 were
frequently recognized and contain no described epitopes to date.
These OLPs were weakly associated with HLA-B*57 expression,
but these associations did not survive multiple test comparisons
(described below, Table S2). Two potential epitopes within these
OLPs, VSGFLALAW and RSIRLVSGF, fit the HLA-B*57
binding motif (Fig. 2a), and we confirmed these as recognizable
epitopes in Elispot assays using PBMCs from HLA-B*57+ subjects
(not shown). These responses were often immunodominant; OLP-
149, where targeted, was typically the strongest Env-specific
response, and pool 23 (containing OLP147, 148, and 149) was the
dominant Env pool in .75% of B*57+ subjects tested (not shown).
The clade B version of this epitope contains aspartic acid at
position 2 in the epitope (Fig. 2b). Because the HLA-B*57 binding
motif prefers alanine, threonine, or serine as position 2 anchors,
this epitope does not appear to be available in clade B, providing a
possible explanation as to why it has yet to be described. Given the
additional differences in clades C and D in this region, it is likely
that these immunodominant epitopes are clade A1-specific.
OLP-156 is another example of a commonly recognized pepitde
in our population (9.8% of subjects) with no decribed epitopes to
date (Table 1). Sequence alignments of this OLP with other clades
demonstrated that while relatively conserved in clade A1, a seven
amino acid stretch is absent in most sequences from clades B and
D, and is substantially different in clade C (not shown). Therefore,
OLP-156 is another example of a clade A1-specific epitope.
Influence of HLA on epitope recognition frequencies
Differences in HLA frequencies between populations may also
contribute to differences in CD8+ T cell epitope recognition
Mapping Clade A1 CD8 Epitopes
PLoS ONE | www.plosone.org 3 September 2009 | Volume 4 | Issue 9 | e6965Figure 1. Influence of HIV diversity on CD8+ T cell epitope recognition frequencies. Epitopes recognized by a Kenyan cohort (n=61) are
shown, with the sequence of the most frequent optimal OLP sequences indicated and the optimal length epitope underlined a). Inverse relationship
between OLP Elispot response frequency (x-axes) and the number of amino acid differences between BDE and ancestral/consensus clade A1 sequence
(left panel) and clade A1 OLP library sequence (right panel) b). Positive selection was more commonly observed in new epitopes compared to BDEs c).
doi:10.1371/journal.pone.0006965.g001
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(16/104) were made by subjects with a previously described HLA
restriction for that BDE. This phenomenon of multiple alleles
presenting the same epitope has been referred to as cross-
restriction. Therefore, 85% of responses detected in this cohort
represent new epitopes and/or new HLA restrictions of described
epitopes. Although the inclusion of HLA supertypes would
increase the number of responses with putative restrictions, this
analysis must be approached with caution given that subtle
differences exist between the epitope restrictions of closely related
alleles [23]. Overall, there was no correlation between the
frequency of HLA alleles known to present BDEs within a
15mer OLP and the response frequency to that OLP (p=0.6, not
shown). These data suggest that subjects are either recognizing
different epitopes within an OLP, or more likely that epitope
recognition commonly occurs in the context of multiple HLA
alleles.
There were several examples that illustrated how HLA
frequency and/or HIV-1 diversity can influence epitope
recognition frequency. OLP-82, which was not recognized
despite being conserved between clades A1 and B, contains two
epitopes restricted by HLA alleles (B*5101 and A*3201) that
are present at low frequencies in our cohort (3 and 3.7%).
Therefore, even though the epitope sequence was available,
the HLA alleles needed to present the epitope were infrequent.
Conversely, some BDEs restricted by common alleles (.10%
in frequency; i.e. HLA-A*3002-HIGPGRAFY and A*0201-
RGPGRAFYVTI) had several sequence differences between
clades A1 and B which could explain their lack of recognition
in our study (Table S1). Finally, for the HLA-A*3101-
restricted epitope RLRDLLLIVTR, a low cohort HLA
frequency (,2%) combined with several sequence differences
correspond to lack of recognition of this OLP in our study.
These data suggest that HLA allele frequency or HIV-1
diversity, and in some cases both, can limit the availability of
BDEs in another population.
We next measured associations between responses to an OLP
and expression of specific HLA alleles by those subjects. We
restricted these analyses to HLA alleles expressed by $5 subjects
(n=36), and OLPs recognized by $4 subjects (n=19), for a total
of 684 comparisons. These analyses also included data from a
recently published report[24] (n$90 tested for most OLPs). We
observed 44 significant associations at the P,0.05 level, and 20 at
P,0.01 (Table S2). Only five associations between OLP
Table 1. OLPs targeted in the current study (by $2 subjects) that are not found on the Best Defined Epitope (BDE) list.
OLP Sequence aligned to
clade B consensus (below)
Overlapping
Peptide (OLP)
Env position
(HXB2)
No. of Responders
(n=61)
Previous descriptions of
epitopes in the region
LVSGFLALAWDDLRN
---D---------I----------
OLP-149 749–63 11 (18.0%) 20mer (742–61) includes this
epitope, no HLA
GRSIRLVSGFLALAW
D---G-----D--------I--
OLP-148 744–58 9 (14.8%)
EQDRGRSIRLVSGFL
--R---D----G-----D-----
OLP-147 739–53 6 (9.8%)
ELLGHSSLKGLRLGW
-------deleted..............
OLP-156 783–97 6 (9.8%) 786–794 (different sequence)
LGNLLLYWGRELKTS
WW-----Q---SQ-----N-
OLP-160 796–810 5 (8.2%) 799–807, different epitope
IKQLQARVLAVERYL
-------------------------
OLP-114 573–87 5 (8.2%) 19mers (570–589, 572–590)
EVHNVWATHACVPTD
-------------------------
OLP-13 64–78 4 (6.5%) described as 20mer (62–80),
no HLA
VRQGYSPLSFQTLTP
--------------------RL--
OLP-141 708–22 4 (6.5%) nothing
IYMENVTEEFNMWKN
VVL---------N----------
OLP-17 84–98 4 (6.5%) A*11, A*68, clade B version
NITNNITNSITNSSV
-----TS--RDKVQKEYA
OLP-27 160–74 4 (6.5%) nothing
LTVWGIKQLQARVLA
-------------------------
OLP-113 568–82 3 (4.9%) see OLP-114
LDCSYNITNNITNSI
KN---F----TS--RDKV
OLP-26 155–69 3 (4.9%) 156–65 Cw8
QHLLKLTVWGIKQLQ
-------Q----------------
OLP-112 563–77 2 (3.3%) 565–573 (A2)
AIEAQQHLLKLTVWG
---------------Q--------
OLP-111 558–72 2 (3.3%) closest is 557–65 w R in front
PNPQEIYMENVTEEF
--------VVL--------N-
OLP-16 79–93 2 (3.3%) 78–86 B*3501, w D in front
SPLSFQTLTPNPRDP
------------RL-A---G--
OLP-142 713–27 2 (3.3%) nothing
Optimal epitopes=underlined.
doi:10.1371/journal.pone.0006965.t001
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comparisons into account (P,0.0001, Boneferoni test). The most
frequently recognized peptide in this population was OLP-169,
recognized by 32% of subjects tested (n=99, not shown). OLP-
169, which contains the B*0702-restricted BDE IPRRIRQGL,
was recognized by 83% (20/24) of HLA-B*4201+ subjects,
compared to 16% (12/75) of B*4201-negative subjects
(P=2.96610
29). Similarly, 88% (7/8) of B*0702+ subjects
recognized OLP-169, while only 27% (25/91) HLA-B*0702-
negative subjects responded to this peptide (P=0.001). Together
these B7 supertype alleles appear to restrict the majority of
responses to OLP-169, which was the immunodominant CD8
epitope in this population.
Predicted versus recognized epitopes for the B7
supertype
Among the methods proposed for the definition of CD8
epitopes, a number of epitope prediction algorithms have been
employed to decrease the number of potential epitopes needing
confirmation in immunological assays. We therefore evaluated the
ability of these algorithms to predict which epitopes would be
targeted in our epitope mapping study. Using motifs that have
been defined for seven HLA supertypes[25] and the clade A1 OLP
library used in our study, a wide range of epitopes were predicted,
depending largely on how narrowly each HLA motif had been
defined (this included 10 epitopes for HLA-B7, 28 for B44, 26 for
A1, 149 for A2, 28 for B27, 115 for A24, and 48 for B58).
We focused our analysis on the HLA-B7 supertype given its
immunodominance in our epitope mapping and association data.
Of the 10 predicted epitopes, only one was recognized in this study
(IPRRIRQGL, contained in OLP-169). Another B7 epitope that
was frequently recognized (OLP-60), RPNNNTRKSI, was
predicted when the analysis was extended to 10mers. Very similar
results were observed when the predictions were repeated with
clade B Env; all 10 epitopes were predicted, plus an additional 3
not predicted for clade A1, suggesting a similar set of epitopes
predicted between clades.
We next examined possible reasons why most predicted
epitopes were not targeted by CD8+ T cells in our population.
We hypothesized that predicted epitopes could go unrecognized
where the autologous HIV sequences in subjects tested differed
from the sequence of the OLP library. We examined the
autologous quasispecies of subjects who possessed a B7 supertype
allele but tested negative for 9/10 of the predicted epitopes (n=4).
Sequence differences between autologous and OLP library were
common in these subjects (Table 2). All of these differences were
observed in non-HLA anchor residues, suggesting that the residues
required for HLA binding remained intact in the autologous
sequences of these subjects. Although we did not test these variants
for T cell responses, it appears that the predicted epitopes were at
least available for HLA presentation in HLA-B7+ subjects who
nevertheless did not recognize them.
To determine experimentally whether predicted epitopes were
capable of binding HLA-B*0702, we tested these peptides in the
ITOPIA
TM in vitro HLA-peptide binding system. These experi-
ments showed that 7/10 of the predicted epitopes bound HLA-
B*0702, as demonstrated by $30% binding as compared to
proprietry control peptide (Table 2). Of the predicted B7 epitopes,
it was the frequently recognized IPRRIRQGL epitope (OLP-169)
which bound to HLA-B*0702 with the strongest affinity (180% of
positive control peptide). Therefore, because several predicted
epitopes were positive for HLA binding in vitro, the lack of
recognition of these peptides in our cohort (and others) could be
because a) this binding is suboptimal for generating responses
when competing with other antigen-specific responses, b) these
responses have been lost through the course of infection, or c) these
epitopes may not be readily processed or recognized by an
appropriate TCR.
We addressed the latter hypothesis using bioinformatics tools
that determined the TAP binding affinity[26] and proteasomal
cleavage scores[27] of predicted B7 epitopes in the context of the
clade A1 OLP library sequence. While all of the predicted but
unrecognized epitopes had low/undetectable TAP scores (mean
1.35, Table 2), IPRRIRQGL had an intermediate TAP score of
3.59, comparable to the mean TAP score of Env BDEs (3.67).
TAP scores did not correlate with the frequency that OLPs were
recognized in our cohort (p=0.3). There were no significant
differences between TAP scores or proteosomal cleavage sites in
clade B consensus as compared to the A1 OLP library in the
overall data set. However, for certain epitopes TAP binding might
influence clade-specific recognition frequencies. For example, the
clade A1 version of EVAQRAYRA (EVGQRLGRA), recognized
by only one subject, had a lower TAP binding score (2.78) as
compared with the BDE (5.11).
OLP responses are associated with altered disease
progression
To determine if recognition of any OLP was associated with
altered progression to various stages of HIV disease progression,
we compared the time to CD4 decline below 500, 350 and 250 in
responders and non-responders for 17 OLPs recognized by $4
subjects (n=61, see methods). Responses to three OLPs were
associated with slower progression to AIDS, and responses to one
OLP with faster progression to AIDS (Fig. 3). OLP-60, -140, and
-160 responders progressed approximately 2–3 times slower than
non-responders to CD4 counts below 500, 200, and 350,
respectively (p,0.05, Mann Whitney, Fig. 3a). In contrast,
OLP-169 recognition was associated with an approximate two-
fold faster time to consecutive CD4 counts below 200 (p=0.031).
Because the same subjects frequently recognized both OLP-60 and
-169, we next compared the effect of recognizing these protective
and detrimental OLPs in combination. Subjects recognizing both,
neither, or OLP-60 only all progress more slowly to CD4,200
Figure 2. OLP-147 and 149 represent clade A1-specific
epitopes. These OLPs associate with HLA-B*57 expression (Table 2)
and with the anchor residues that have been defined for the HLA-B*57
binding motif a). Alignments of the optimal epitope within OLP-149
demonstrate that in other clades, this epitope would not likely be
presented by HLA-B*57 b).
doi:10.1371/journal.pone.0006965.g002
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data were observed for CD4,500. Interestingly, while both HLA-
B*0702 and B*4201 associated with OLP-169 recognition, the
related allele B*8101, which is the B7 allele most strongly
associated with lower viral loads in other studies[28], was not
associated with OLP-169 recognition (P=0.8). While causation
cannot be inferred in a cross-sectional study, these data suggest
recognition of certain OLPs may be beneficial or detrimental in
the setting of chronic HIV infection.
Discussion
The genetic diversity of HIV-1 is a major obstacle to both an
accurate measurement of host immune responses and the design of
successful HIV-1 vaccines. Historically, HIV-specific CD8+ T cell
responses have been defined primarily in clade B-infected subjects,
which account for a small minority of the global HIV-1 pandemic.
We evaluated HIV-specific CD8+ T cell responses in a Kenyan
cohort primarily infected with clade A1 (.75%)[29]. The majority
of epitopes on the Best Described Epitope list were indeed recognized
by these subjects (69%, 18/26). Exceptions were found in either
direction; several BDEs were not recognized in our cohort (n=8,
Table 1), and several responsive OLPs in our cohort did not
contain BDEs (n=16, Table S1). The reasons for differences in
epitope recognition between populations are likely numerous,
given the number of host and viral factors that can influence
recognition frequencies of CD8+ T cell epitopes. Our data suggest
that sequence differences between BDEs and clade A1 may play a
role in determining which BDEs were recognized. In addition,
while many epitopes have now been defined, almost half of
responsive epitopes (47%) recognized by $2 subjects in our study
have yet to be described, suggesting that these efforts have not
been entirely exhausted. This has been supported by a recent
study which found that even for well studied HLA alleles,
prediction software and in vitro immunological confirmations were
able to define several new epitopes[30].
A wide array of host and viral determinants influence which
epitopes result in immune responses. Host factors often depend on
viral sequences, particularly where differences in viral sequence
affect how an epitope is processed, presented, and recognized by
T cells. Amino acid substitutions can be extra-epitopic, including
those that affect epitope processing, or intra-epitopic, such as
those that affect TAP binding, HLA binding, and TCR
recognition. In the case of HLA-B7, we found that only one of
the in silico predicted Env epitopes was frequently recognized in
our Kenyan cohort. Many of the HLA-B7 subjects we tested
possessed autologous sequences that differed from the clade A1
Env OLP library sequence, although the immunological conse-
quences of these substitutions remain unknown. In addition, all of
the predicted but unrecognized epitopes had low TAP binding
Table 2. Predicted epitopes based on the HLA-B7 supertype motif and the clade A1 OLP library sequence used for epitope
mapping.
U15119 position Seqence TAP binding scores* ITOPIA HLA-B*0702 binding (%)** Autologous Seq.***
8–16 YPCWWTWGI 2.893 none no data
75–83 DPNPQEIYM 20.901 none DPNPQEIEL
DPNPREISL
DPNPQEIPL
DPNPQEVVL
114–22 KPCVQLTPL 2.175 64.2
(----K----)
KPCVKLTPL
KPCVQLTPL
KPCVKLTPL
KPCVKLTPL
205–13 CPKVTFEPI 21.025 30.1 CPKVNFEPI
CPKVTFEPI
CPKVSFEPI
CPKVTFEPI
211–9 EPIPIRYCA 2.869 none EPIPIHYCA
EPIPIHYCA
EPIPIHYCA
EPIPIHYCA
213–21 IPIRYCAPA 0.198 58.5
(---H-----)
IPIHYCAPA
IPIHYCAPA
IPIHYCAPA
IPIHYCAPA
252–60 RPVVSTQLL 1.393 78.1 KPVVSTQLL
KPVVSTQLL
KPVVSTQLL
KPVVSTQLL
408–16 LPCRIKQII 2.046 75.9 no data
489–497 APTKAKRRV 2.482 95.2 no data
843–51 IPRRIRQGL 3.59 (intermed) 180.2 no data
Only the last epitope (in bold) was recognized.
*TAP binding scores were calculated using TAPpred, as per Ref. 20.
**Percentage of Positive control binding. Where ITOPIA-tested sequences differed from OLP, these are noted.
***Autologous sequences are from HLA B7 supertype+ subjects who did not recognize the epitopes listed (except IPRRIRQGL). Each sequence=1 subject.
doi:10.1371/journal.pone.0006965.t002
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B*0702 in vitro. This suggests that while some of the predicted
epitopes can bind HLA-B*0702, this binding may be sub-optimal
in vivo, and moreover that other upstream factors may influence
how well these predicted epitopes are loaded onto HLA and
presented to T cells. This in turn would limit the number of
epitopes for any given HLA allele at the population level. Because
competition between T cell clones is believed to be an important
determinant of immunodominance[31], better TAP and HLA
binding could influence the amount of HLA-epitope that is
available to stimulate a corresponding T cell response. The
quality of TCR recognition is also likely to be critical, particularly
the functional avidity of the HLA-epitope-TCR interactions.
Previous work has demonstrated that HLA binding alone did
not predict the recognition frequency of HIV and EBV
epitopes[32].
These epitope mapping data corroborate our previous study in
this population showing that while substantial cross-clade
reactivity was present, there were also a subset of subjects who
displayed a preference for clade A1[8]. This has since been
supported by other studies of mixed clade infections[33]. The data
presented here suggest that recognition of a combination of
common and clade-specific epitopes provides a plausible explana-
tion for our prior clade A1 preference data. We identified
examples of novel, clade A1-specific epitopes (OLP-149, 156) that
were recognized frequently in our cohort. Neither of these epitopes
was available in a presentable form in most clade B (and other
clade) sequences, and therefore subjects infected by clade B would
not likely be exposed to these peptides, even though they could
have HLA alleles capable of presenting, and TCRs capable of
responding. These data suggest that each clade may have
additional epitopes, not available in other clades, which could
Figure 3. Recognition of certain OLPs was associated with clinical progression status. Three OLPs were associated with slower
progression, and one with faster progression a). Recognition of OLP-060 and -169 in combination and implications for disease progression b).
doi:10.1371/journal.pone.0006965.g003
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infected by these clades.
We found some associations between particular HLA class I
alleles and responses to particular OLPs. Although our study was
underpowered and therefore exploratory, other factors may
impede the definition of HLA restriction by this method. For
example, although OLP-7 was recognized by almost 25% of
subjects, only one weak HLA association was observed (Table S2).
A probable explanation for these data is that OLP-7 is
promiscuous and can be presented by more than one HLA allele,
as has been previously described[34], and therefore, a very large
study would be required to identify its HLA restriction(s). Another
instance where statistical power is lacking is the case where an
epitope is not commonly recognized by subjects expressing the
restricting allele. An example is the association between OLP-27
and B*1503; while all 4 subjects who recognized OLP-27
expressed HLA-B*1503, only 4/22 B*1503+ subjects responded
to OLP-27 (P=0.005). Therefore, although HLA-B*1503 appears
to be the presenting allele, it remains inconclusive without
immunological confirmation.
Although Env-specific CD8+ T cell responses have previously
been associated with higher viral loads, here we find that three Env
epitopes associated with slower progression. While these are only
associations and not proof of causation, it is possible that not all
Env epitopes are detrimental in the setting of HIV infection.
Conversely, the dominant Env epitope in this study (B7 supertype-
restricted OLP-169) was associated with worse clinical outcome,
raising the possibility that responses to certain epitopes can distract
attention away from epitopes that are better capable of providing
protection. One way to address this hypothesis would be to
examine the relationship between protective and non-protective
epitopes; if ‘‘bad’’ epitopes distract the immune system away from
‘‘good’’ responses, then one might predict there to be an inverse
relationship, with a response to bad epitopes detracting from
responses to good epitopes. Here we provide preliminary evidence
that recognition of the protective epitope (OLP-060) may be
advantageous even if the detrimental epitope (OLP-169) is
recognized concurrently. These data will need to be confirmed
in larger studies.
Previous studies have compared epitope recognition between
HIV-infected populations. One report found that multiple
ethnicities infected by clade B target similar immunodominant
regions of HIV-1[2]. Clade C has also been the focus of some
recent studies, including those in Southern Africa, India, and
Ethiopia, all of which find similar epitope regions were targeted in
respective clade C epidemics compared to clade B and other clade
C-infected populations[35,36,37,38]. Some instances of clade and
region-specifc responses have also been observed. In China, where
clade B/C recombinants dominate, clade B OLP responses tended
to be higher magnitude when testing regions of HIV-1 that were
predominantly clade B, and vice versa for clade C[39]. Our data
also agree with another Kenyan study, which found that many
CD8 responses in clade A were common to those found in clades B
and C, and that additional OLP libraries do not appreciably
increase the frequency of responses detected[40]. Therefore,
although many responses are shared between clades, a consensus
on the degree to which additional responses can be detected, and
the clinical relevance of these responses, remains an important
area of HIV vaccine research.
A more accurate definition of HIV-specific CD8+ T cell
responses remains critical, both for assessment of HIV vaccine
candidates and for a better definition of CD8+ T cell responses
capable of delaying progression to AIDS. Here we have
demonstrated that while the majority of BDEs were relevant in
this Kenyan population, a number of additional OLPs without
BDEs were frequently recognized. While sequence differences
between clade A1 (dominant in Kenya) and B (focus of most studies)
often appear to be capable of explaining these differences, a number
of host factors also contribute to the recognition frequency of OLPs
inourstudy.Asaresult,some importantimmunologicaltargetsmay
be clade-specific and therefore not detected in studies of other
clades, even though they could remain useful for HIV-1 vaccine
design. These data suggest that subtle differences in HIV-specific
immunity exist between populations, with potential implications for
approximating the breadth of vaccine coverage.
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